Akeso, Summit's ivonescimab delayed progression of certain lung cancers in first global phase 3 readout
In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab significantly reduced the risk of progression or death by 48% in patients with previously treated EGFR-mutated nonsquamous non-small cell lung cancer.
In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab significantly reduced the risk of progression or death by 48% in patients with previously treated EGFR-mutated nonsquamous non-small cell lung cancer.
